Topics

Chemistry & Life Sciences

Expert Statement: Frank Wegener, ESIM Chemicals

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Chad Telgenhof, Sterling Pharma Solutions

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Ludwig de Mot, EuroAPI

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Alex Del Priore, Syngene

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Kenneth N. Drew, Flamma

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Greg Behar, Recipharm

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Gordon Bates, Lonza

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Jordi Robinson, Navin Molecular

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.